• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥厚型 Fabry 病的心脏表型。

Cardiac Phenotype of Prehypertrophic Fabry Disease.

机构信息

Cardiology Department, Barts Heart Centre, London, United Kingdom (S.N., A.A.-G., K.M.-M., S.R., G.C., J.C.M.).

Institute of Cardiovascular Science, University College London, United Kingdom (S.N., A.A.-G., K.M.-M., G.C., J.C.M.).

出版信息

Circ Cardiovasc Imaging. 2018 Jun;11(6):e007168. doi: 10.1161/CIRCIMAGING.117.007168.

DOI:10.1161/CIRCIMAGING.117.007168
PMID:29853467
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6023585/
Abstract

BACKGROUND

Fabry disease (FD) is a rare and treatable X-linked lysosomal storage disorder. Cardiac involvement determines outcomes; therefore, detecting early changes is important. Native T1 by cardiovascular magnetic resonance is low, reflecting sphingolipid storage. Early phenotype development is familiar in hypertrophic cardiomyopathy but unexplored in FD. We explored the prehypertrophic cardiac phenotype of FD and the role of storage.

METHODS AND RESULTS

A prospective, international multicenter observational study of 100 left ventricular hypertrophy-negative FD patients (mean age: 39±15 years; 19% male) and 35 age- and sex-matched healthy volunteers (mean age: 40±14 years; 25% male) who underwent cardiovascular magnetic resonance, including native T1 and late gadolinium enhancement, and 12-lead ECG. In FD, 41% had a low native T1 using a single septal region of interest, but this increased to 59% using a second slice because early native T1 lowering was patchy. ECG abnormalities were present in 41% and twice as common with low native T1 (53% versus 24%; =0.005). When native T1 was low, left ventricular maximum wall thickness, indexed mass, and ejection fraction were higher (maximum wall thickness 9±1.5 versus 8±1.4 mm, <0.005; indexed left ventricular mass 63±10 versus 58±9 g/m, <0.05; and left ventricular ejection fraction 73±8% versus 69±7%, <0.01). Late gadolinium enhancement was more likely when native T1 was low (27% versus 6%; =0.01). FD had higher maximal apical fractal dimensions compared with healthy volunteers (1.27±0.06 versus 1.24±0.04; <0.005) and longer anterior mitral valve leaflets (23±2 mm versus 21±3 mm; <0.005).

CONCLUSIONS

There is a detectable prehypertrophic phenotype in FD consisting of storage (low native T1), structural, functional, and ECG changes.

摘要

背景

法布里病(FD)是一种罕见的可治疗的 X 连锁溶酶体贮积症。心脏受累决定了预后,因此,早期发现变化很重要。心血管磁共振的心肌 T1 弛豫时间(native T1)值较低,反映了鞘脂的贮积。肥厚型心肌病的早期表型已广为人知,但 FD 中的表型发展尚不清楚。我们探讨了 FD 的心肌肥厚前表型以及贮积的作用。

方法和结果

一项前瞻性、国际性多中心观察研究纳入了 100 例左心室肥厚阴性 FD 患者(平均年龄:39±15 岁;19%为男性)和 35 名年龄和性别匹配的健康志愿者(平均年龄:40±14 岁;25%为男性),他们接受了心血管磁共振检查,包括 native T1 和钆延迟增强,以及 12 导联心电图。FD 患者中,41%的人使用单个室间隔感兴趣区的 native T1 值较低,但使用第二张切片时,这一比例增加到 59%,因为早期 native T1 值降低呈斑片状。41%的患者存在心电图异常,而 native T1 值较低时更为常见(53%与 24%;=0.005)。当 native T1 值较低时,左心室最大壁厚度、指数化质量和射血分数更高(最大壁厚度 9±1.5 与 8±1.4 mm,<0.005;指数化左心室质量 63±10 与 58±9 g/m,<0.05;左心室射血分数 73±8%与 69±7%,<0.01)。当 native T1 值较低时,更可能出现钆延迟增强(27%与 6%;=0.01)。FD 患者的最大心尖分形维数高于健康志愿者(1.27±0.06 与 1.24±0.04;<0.005),且前二尖瓣瓣叶较长(23±2 mm 与 21±3 mm;<0.005)。

结论

FD 存在可检测到的心肌肥厚前表型,包括贮积(native T1 值较低)、结构、功能和心电图变化。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/ee1ae2503f30/hci-11-e007168-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/c6a79d8af44c/hci-11-e007168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/11dd358e2d0a/hci-11-e007168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/41fe6fd2a77c/hci-11-e007168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/9bf59a5968aa/hci-11-e007168-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/ee1ae2503f30/hci-11-e007168-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/c6a79d8af44c/hci-11-e007168-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/11dd358e2d0a/hci-11-e007168-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/41fe6fd2a77c/hci-11-e007168-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/9bf59a5968aa/hci-11-e007168-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cac7/6023585/ee1ae2503f30/hci-11-e007168-g008.jpg

相似文献

1
Cardiac Phenotype of Prehypertrophic Fabry Disease.肥厚型 Fabry 病的心脏表型。
Circ Cardiovasc Imaging. 2018 Jun;11(6):e007168. doi: 10.1161/CIRCIMAGING.117.007168.
2
Proposed Stages of Myocardial Phenotype Development in Fabry Disease.法布里病心肌表型发育的拟议阶段。
JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 2):1673-1683. doi: 10.1016/j.jcmg.2018.03.020. Epub 2018 May 16.
3
Global longitudinal strain, myocardial storage and hypertrophy in Fabry disease.法布瑞氏病患者的心肌纵向应变、心肌贮备和心肌肥厚。
Heart. 2019 Mar;105(6):470-476. doi: 10.1136/heartjnl-2018-313699. Epub 2018 Oct 3.
4
Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy.酶替代治疗 1 年后法布病患者心肌储存、炎症和心脏表型。
Circ Cardiovasc Imaging. 2019 Dec;12(12):e009430. doi: 10.1161/CIRCIMAGING.119.009430. Epub 2019 Dec 12.
5
Loss of base-to-apex circumferential strain gradient assessed by cardiovascular magnetic resonance in Fabry disease: relationship to T1 mapping, late gadolinium enhancement and hypertrophy.通过心血管磁共振评估法布里病的基底-顶点周向应变梯度缺失:与 T1 映射、晚期钆增强和心肌肥厚的关系。
J Cardiovasc Magn Reson. 2019 Aug 1;21(1):45. doi: 10.1186/s12968-019-0557-0.
6
Predictors of Clinical Evolution in Prehypertrophic Fabry Disease.肥厚型 Fabry 病临床演变的预测因素。
Circ Cardiovasc Imaging. 2019 Apr;12(4):e008424. doi: 10.1161/CIRCIMAGING.118.008424.
7
The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage.法布瑞氏病心肌表型的肥大前期和可检测存储前期。
Eur Heart J Cardiovasc Imaging. 2021 Jun 22;22(7):790-799. doi: 10.1093/ehjci/jeaa101.
8
Assessment of Cardiac Involvement in Fabry Disease (FD) with Native T1 Mapping.采用原生T1成像评估法布里病(FD)患者的心脏受累情况。
Rofo. 2019 Oct;191(10):932-939. doi: 10.1055/a-0836-2723. Epub 2019 Feb 12.
9
Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance.天然心肌T1映射在法布里病评估中的可重复性及其在心血管磁共振早期检测心脏受累中的作用。
J Cardiovasc Magn Reson. 2014 Dec 5;16(1):99. doi: 10.1186/s12968-014-0099-4.
10
T₁ mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex.心血管磁共振 T₁ 映射对于法布里病具有高度敏感性,与肥大和性别无关。
Circ Cardiovasc Imaging. 2013 Sep;6(5):637-45. doi: 10.1161/CIRCIMAGING.113.000482. Epub 2013 Aug 6.

引用本文的文献

1
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies.法布里病:对病理生理学和新型治疗策略的见解
Biomedicines. 2025 Mar 4;13(3):624. doi: 10.3390/biomedicines13030624.
2
Anderson-Fabry Disease: An Overview of Current Diagnosis, Arrhythmic Risk Stratification, and Therapeutic Strategies.安德森-法布里病:当前诊断、心律失常风险分层及治疗策略概述
Diagnostics (Basel). 2025 Jan 9;15(2):139. doi: 10.3390/diagnostics15020139.
3
Spns1-dependent endocardial lysosomal function drives valve morphogenesis through Notch1-signaling.

本文引用的文献

1
Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice.法布瑞病患者的室性心律失常和心源性猝死:临床实践中风险因素的系统综述。
Europace. 2018 Sep 1;20(FI2):f153-f161. doi: 10.1093/europace/eux261.
2
Community delivery of semiautomated fractal analysis tool in cardiac mr for trabecular phenotyping.心脏磁共振中半自动分形分析工具的社区应用:小梁表型分析。
J Magn Reson Imaging. 2017 Oct;46(4):1082-1088. doi: 10.1002/jmri.25644. Epub 2017 Feb 2.
3
Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy.
Spns1 依赖的心内膜溶酶体功能通过 Notch1 信号传导驱动瓣膜形态发生。
iScience. 2024 Nov 19;27(12):111406. doi: 10.1016/j.isci.2024.111406. eCollection 2024 Dec 20.
4
Role of standard echocardiography in Anderson-Fabry disease.标准超声心动图在安德森-法布里病中的作用。
Front Cardiovasc Med. 2024 Oct 24;11:1467815. doi: 10.3389/fcvm.2024.1467815. eCollection 2024.
5
Cardiovascular magnetic resonance insights into anomalies of the mitral valve apparatus in Fabry cardiomyopathy and hypertrophic cardiomyopathy.心血管磁共振对法布里心肌病和肥厚型心肌病二尖瓣装置异常的见解。
Front Cardiovasc Med. 2024 Sep 30;11:1458705. doi: 10.3389/fcvm.2024.1458705. eCollection 2024.
6
Inflammation, Oxidative Stress, and Endothelial Dysfunction in the Pathogenesis of Vascular Damage: Unraveling Novel Cardiovascular Risk Factors in Fabry Disease.在血管损伤发病机制中的炎症、氧化应激和内皮功能障碍:法布里病中新型心血管风险因素的研究。
Int J Mol Sci. 2024 Jul 29;25(15):8273. doi: 10.3390/ijms25158273.
7
Cardiac Magnetic Resonance Features of Fabry Disease: From Early Diagnosis to Prognostic Stratification.法布里病的心脏磁共振特征:从早期诊断到预后分层
Rev Cardiovasc Med. 2022 May 16;23(5):177. doi: 10.31083/j.rcm2305177. eCollection 2022 May.
8
Fabry Disease Cardiomyopathy: A Review of the Role of Cardiac Imaging from Diagnosis to Treatment.法布里病心肌病:从诊断到治疗的心脏成像作用综述
Rev Cardiovasc Med. 2022 May 27;23(6):192. doi: 10.31083/j.rcm2306192. eCollection 2022 Jun.
9
Effects of Enzyme Replacement Therapy on Cardiac MRI Findings in Fabry Disease: A Systematic Review and Meta-Analysis.酶替代疗法对法布里病心脏 MRI 表现的影响:系统评价和荟萃分析。
Radiol Cardiothorac Imaging. 2024 Jun;6(3):e230154. doi: 10.1148/ryct.230154.
10
The Role of Magnetic Resonance Imaging in Cardiomyopathies in the Light of New Guidelines: A Focus on Tissue Mapping.根据新指南探讨磁共振成像在心肌病中的作用:聚焦组织成像
J Clin Med. 2024 Apr 29;13(9):2621. doi: 10.3390/jcm13092621.
伴有延迟钆增强的心脏法布里病是一种慢性炎症性心肌病。
J Am Coll Cardiol. 2016 Oct 11;68(15):1707-1708. doi: 10.1016/j.jacc.2016.07.741.
4
A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance-the T Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) program.用于全球T1映射质量保证的医疗设备级T1和ECV体模——心血管磁共振成像中的T映射与ECV标准化(T1MES)项目
J Cardiovasc Magn Reson. 2016 Sep 22;18(1):58. doi: 10.1186/s12968-016-0280-z.
5
Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping.洞悉心肌肥厚:一项基于心脏磁共振研究乳头肌质量和 T1 映射的研究。
Eur Heart J Cardiovasc Imaging. 2017 Sep 1;18(9):1034-1040. doi: 10.1093/ehjci/jew187.
6
Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat.米加司他治疗法布里病的疗效。
N Engl J Med. 2016 Aug 11;375(6):545-55. doi: 10.1056/NEJMoa1510198.
7
The embryological basis of subclinical hypertrophic cardiomyopathy.亚临床肥厚型心肌病的胚胎学基础。
Sci Rep. 2016 Jun 21;6:27714. doi: 10.1038/srep27714.
8
Cardiac Troponin I: A Valuable Biomarker Indicating the Cardiac Involvement in Fabry Disease.心肌肌钙蛋白I:一种表明法布里病中心脏受累情况的重要生物标志物。
PLoS One. 2016 Jun 20;11(6):e0157640. doi: 10.1371/journal.pone.0157640. eCollection 2016.
9
The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy.心电图参数作为法布里心肌病治疗反应标志物的价值。
Heart. 2016 Aug 15;102(16):1309-14. doi: 10.1136/heartjnl-2015-308897. Epub 2016 Apr 7.
10
Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR.通过心血管磁共振评估基因型阳性法布里病患者的心脏受累情况。
Heart. 2016 Feb 15;102(4):298-302. doi: 10.1136/heartjnl-2015-308494. Epub 2016 Jan 4.